Second Genome, Inc., a leader in the development of novel medicines derived from the human microbiome, today announced the presentation of preclinical data and results from a Phase 1 study in... read more
Second Genome, Inc., a leader in the development of novel medicines derived from the human microbiome, today announced the presentation of preclinical data and results from a Phase 1 study in... read more
Researchers from the University of Illinois at Chicago and Nosopharm, a biotechnology company based in Lyon, France, are part of an international team reporting on the discovery of a new class of... read more
The article discusses the concern over the number of deaths (244) and other adverse events linked to nuplazid. The drug was approved in April of 2016 as a much needed treatment for Parkinson's... read more
BioCardia®, Inc., [OTC: BCDA] a leader in cardiovascular regenerative medicine, today announced the publication of the Phase III CardiAMP Heart Failure Trial design paper in the American Heart... read more
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the U.S. Food and Drug Administration (FDA) has approved Rubraca® (rucaparib) tablets for the maintenance treatment of adult patients with... read more